ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Aberrant phase separation from a rare ABI3 mutation drives microglial dysfunction and Alzheimer's risk.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
introductionAlthough the ABI3 S209F variant is a recognized genetic risk for Alzheimer's disease (AD), its pathogenic mechanism remains elusive.
methodsUsing AD mouse models (amyloid precursor protein/presenilin 1 [APP/PS1] transgenic mice, 5×familial Alzheimer's disease (5×FAD) transgenic mice) with microglia-specific knockdown of Abelson-interactor family member 3 (ABI3) or expression of the wild-type or S209F mutant, we assessed disease pathology. Primary mouse microglia and HMC3 cells were used to examine ABI3 function and S209F effects. Liquid-liquid phase separation (LLPS) properties were characterized in cellular systems and with recombinant proteins.
resultsABI3 was highly expressed in AD microglia. ABI3 enhanced microglial clustering around amyloid beta (Aβ) plaques, promoted Aβ clearance, and ameliorated cognitive decline, whereas S209F abolished these effects. Mechanistically, ABI3 undergoes LLPS essential for microglial migration and phagocytosis. The S209 residue lies within an intrinsic disordered region, and S209F disrupts phosphorylation-dependent LLPS, thereby impairing microglial functions. DISCUSSION: The AD-associated ABI3 S209F variant drives pathogenesis by disrupting LLPS, causing microglial dysfunction. Enhancing ABI3 phase separation represents a potential therapeutic strategy to boost microglial activity against Aβ pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.